Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
Orchestra BioMed Holdings, Inc. announced two presentations regarding their Atrioventricular Interval Modulation (AVIM) Therapy at the Heart Rhythm Society (HRS) 2026 Annual Meeting. The presentations will showcase new data on the therapy’s effectiveness in reducing blood pressure in patients with hypertensive heart disease and its hemodynamic effects compared to standard pacing. AVIM Therapy is being developed for the treatment of uncontrolled hypertension and has received FDA Breakthrough Device Designation.
NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two AVIM Therapy presentations at the Heart Rhythm Society (HRS) 2026 Annual Meeting.